{
    "medicine_id": "a563c3028dea153d35bc14d1ea71979c28967389",
    "platform_id": "DB04943",
    "metadata": {
        "name": "Fulyzaq 125 mg 1 Tablet coated",
        "composition": "125 mg 1 LX201",
        "clinical_particulars": {
            "therapeutic_indications": "Investigated for use treatment in eye disorders infections and transplant rejection",
            "contraindications": {
                "disease": "NA",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "LX201 is a sustained release silicone implant containing 30 cyclosporine A CsA by weight The LX201 implant releases the cyclosporine at steady doses over the course of a year Local delivery of CsA through LX201 potentially offers significant benefits in the treatment of corneal transplantation due to i increased safety resulting from the absence of systemic toxicity of CsA in particular of renal toxicity as based on animal studies LX201 does not produce measurable systemic levels ii increased efficacy as based on animal studies LX201 can establish continuous and relatively high therapeutic levels of CsA higher than could be established by tolerable oral doses at or near the transplanted cornea and iii increased patient compliance as the implant is hardly perceptible by the patient and dosing cannot be missed throughout the first year after transplantation",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}